Virotherapy of the Malignant U87 Human Glioblastoma in the Orthotopic Xenotransplantation Mouse SCID Model

Abstract

The possibility of glioblastoma virotherapy at intravenous injection of the LIVP–GFP recombinant virus was studied in experimental model of orthotopic xenotransplantation of human glioblastoma cell line U87 to SCID laboratory mice. The LIVP–GFP recombinant virus deficient for thymidine kinase exhibited a significantly greater oncolytic capacity than the original LIVP virus, and an intravenous injection of LIVP–GFP at the early stages of tumorigenesis in mouse brain in most cases resulted in the lysis of the tumor.